01:34 , Nov 1, 2012 |  BC Extra  |  Financial News

Synthetic Biologics raises $10.8 million

Synthetic Biologics Inc. (NYSE-M:SYN) raised about $10.8 million on Wednesday through the sale of about 6.8 million shares at $1.60 in a private placement to new and existing investors. The price is a 31% discount...
00:22 , Oct 30, 2012 |  BC Extra  |  Financial News

Synthetic Biologics to raise $10.9 million

Synthetic Biologics Inc. (NYSE-M:SYN) said it plans to raise about $10.9 million through the sale of 6.8 million shares at $1.60 in a private placement to new and existing investors. The price is a 31%...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Intrexon, Synthetic Biologics deal

Intrexon granted Synthetic Biologics (formerly Adeona Pharmaceuticals Inc.) exclusive, worldwide rights to develop and commercialize mAbs for three undisclosed infectious disease indications using Intrexon's technologies. The deal includes Intrexon's UltraVector technology for assembling transgenes...
00:58 , Aug 9, 2012 |  BC Extra  |  Company News

Intrexon, Synthetic Biologics in infectious disease deal

Intrexon Corp. (Blacksburg, Va.) granted Synthetic Biologics Inc. (NYSE-M:SYN) exclusive, worldwide rights to develop and commercialize mAbs for three undisclosed infectious disease indications using Intrexon's technologies, including the UltraVector technology for assembling transgenes and its...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Clinical News

Trimesta: Completed Phase II enrollment

Synthetic Biologics (formerly Adeona Pharmaceuticals Inc.) completed enrollment of 164 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 8 mg Trimesta daily plus Copaxone glatimer acetate for 2 years. Teva...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Adeona management update

Adeona Pharmaceuticals Inc. (NYSE-A:AEN), Ann Arbor, Mich.   Business: Autoimmune   Hired: C. Evan Bellantyne as CFO, formerly EVP and CFO of Clinical Data Inc., which Forest Laboratories Inc. acquired; and Jeff Riley, chairman, as...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Adeona management update

Adeona Pharmaceuticals Inc. (NYSE-A:AEN), Ann Arbor, Mich.   Business: Autoimmune   Hired: John Monahan as SVP of R&D, founder and formerly CEO of Avigen Inc., which MediciNova Inc. acquired   ...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Adeona, Intrexon deal

Intrexon's Human Therapeutics Division granted Adeona exclusive, worldwide rights to develop and commercialize a DNA-based therapeutic to treat pulmonary arterial hypertension (PAH). The therapeutic uses Intrexon's UltraVector technology for assembling transgenes and its RheoSwitch Therapeutic...
08:00 , Nov 21, 2011 |  BC Week In Review  |  Clinical News

Trimesta: Phase II started

Adeona began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate Trimesta in 64 relapsing-remitting or secondary-progressive female MS patients. The Skirball Foundation and Adeona will equally support the trial. Adeona Pharmaceuticals Inc. (NYSE-A:AEN), Ann...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Adeona board of directors update

Adeona Pharmaceuticals Inc. (NYSE-A:AEN), Ann Arbor, Mich.   Business: Autoimmune   Appointed: Jeff Riley as non-executive chairman; he succeeds James Kuo, who remains CEO, president and a director   ...